SEATTLE, Wash. and VANCOUVER, British Columbia, June 15, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, June 11, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that cytisine data, generated in collaboration with the University of Bristol, was published in Chem. These data show that via the…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, May 23, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, May 9, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced first quarter 2018 financial results and recent highlights. First-Quarter 2018 Highlights Announced preliminary results from a Phase I/II clinical study evaluating…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, May 7, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that the UK Intellectual Property Office has granted Achieve a patent (no. 2550241) on cytisine succinate salt. Cytisine is a plant-based…
/Read More